October 2013

The latest from Cogstate, leaders in optimizing the measurement of cognition

Dr. Robert McCue Joins Cogstate Science Team

October 20, 2013

Cogstate is excited to announce that Dr. Robert McCue has joined our renowned science team. Dr. McCue will oversee and execute our scales management, rater training, and central monitoring services. Scales and neuropsychological tests are highly specialized instruments, which require both scientific and clinical experience to ensure their reliable and valid use in clinical trials […]

Cogstate Opens European Office In Barcelona

October 17, 2013

To respond to the growing needs of our European customers, Cogstate is proud to announce the opening of a new office at the Parc Cientific of Barcelona (PCB), located at the center of one of the most dynamic economic areas of Spain. This location will consolidate Cogstate’s footprint across European countries, as well as offering support […]

New Data Demonstrate Cognigram As A Sensitive Assessment To Detect And Monitor Cognitive Decline

October 8, 2013

Today, Cogstate (CGS:ASX) released important new evidence from partner Merck supporting Cognigram™ as a sensitive assessment to detect and monitor cognitive decline over time in healthy individuals and adults with mild cognitive impairment and who are also carriers of a biological marker in the brain – Aβ amyloid. “This is a true advance in the […]

Cognitive Dysfunction Also Present In Patients With Depression

October 5, 2013

For the 350 million people around the world who suffer from depression, having their physicians, family and friends truly understand their battle has been an ongoing struggle.  Common symptoms such as change in sleep, appetite and energy combined with a lack of interest, low self-esteem and hopelessness create an image of depression being just an […]

Cogstate Computerized Tests Detect Subtle Changes In Cognition

October 2, 2013

At this week’s Autumn Conference of the International Society for CNS Clinical Trials and Methodology (ISCTM) in Philadelphia, Judith Jaeger PhD, VP of Clinical Trials at Cogstate, presented a poster summarizing a study conducted for AstraZeneca in collaboration with the Center for Human Drug Research in Leiden, the Netherlands. Along with Paul Maruff PhD, Cogstate’s Chief Science Officer, […]

Measuring The Cognitive Improvement Of A Fragile X Treatment

October 1, 2013

When Lisa Kowal signed up her 18-year-old son Alex for a clinical trial of a new treatment for Fragile X Syndrome, she knew the 9 ½ hour drive from her home in Buffalo, NY to the test site at Rush University Medical Center in Chicago would be challenging.  As a common symptom of Fragile X, […]